Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Proceedings of the National Academy of Sciences / PubMed
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Arvinas announced an ASH poster on preliminary Phase 1 findings for oral BCL6 degrader ARV-393, also called zaloblideg, in relapsed or refractory non-Hodgkin lymphoma. The December 14 presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in T-cell lymphomas. The announcement itself does not provide numerical response results.
Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.
IDT and Aldevron launched PE Ultra prime-editor mRNA, chemically modified pegRNAs, and six ABE8e-based editor mRNAs with a parallel screening kit. The companies also described guide-design support and stocked quantities from 20 micrograms to 1 milligram. These are research-use products; the announcement does not establish clinical safety, efficacy, or approval.
Umoja announced four accepted ASH presentations, including clinical data from investigator-initiated studies of CD22-directed UB-VV400 in B-cell malignancies and UB-VV410 in lupus. Separate trial-in-progress posters concern UB-VV400 and BCMA/GPRC5D-directed UB-VV500. The announcement schedules December presentations rather than providing numerical response or safety results from those studies.
Tessera announced three preclinical presentations for the December 2026 ASH meeting. Topics include targeted LNP delivery for functional CAR-T generation in nonhuman primates and in vivo hematopoietic stem-cell editing for sickle cell disease. This is a company announcement of upcoming presentations, not a peer-reviewed publication or evidence of clinical benefit.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.
BioPharm International reported Shilpa CDMO's plan to invest $50 million in peptide manufacturing at Raichur, India. The phased expansion would add 10 kiloliters of solid-phase synthesis reactor capacity, beginning with a commercial line planned for December 2026. Commercial supply is expected to ramp during 2027; these are planned capabilities rather than demonstrated utilization.
In a company-issued release carried by BioSpace, Strand announced SITC presentations on intratumoral STX-001 and systemic STX-003, both self-replicating mRNA approaches expressing IL-12. The presentations cover updated STX-001 clinical findings and ASCENT-1 trial design for STX-003. The release does not provide numerical response rates or establish efficacy for systemic administration.
Continue your research
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
